CAJ | 학술논문

目的：比较聚乙二醇干扰素α-2a与恩替卡韦治疗慢性乙型肝炎患者的疗效与安全性。方法将60例慢性乙型肝炎患者随机分为干扰素组30例和恩替卡韦组30例；2组均常规护肝治疗。干扰素组给予聚乙二醇干扰素α-2a，恩替卡韦组另予恩替卡韦，观察治疗30周后2组患者的临床疗效。结果治疗后，2组丙氨酸氨基转肽酶（ALT）、天冬氨酸氨基转肽酶（AST）及总胆红素（TBIL）与治疗前比较，肝功能均有所改善（P<0.05）；恩替卡韦组的ALT复常率（53.3%）、TBIL 复常率（33.3%）和 HBV-DNA 转阴率（36.7%）明显高于干扰素组的 ALT 复常率（46.7%）、TBIL复常率（30.0%）和HBV-DNA转阴率（20.0%），差异有统计学意义（ P<0.05）；干扰素组（43.3%）的不良反应发生率高于恩替卡韦组（10.0%），差异有统计学意义（ P<0.05）。结论恩替卡韦用于慢性乙型肝炎的抗病毒疗效明显优于聚乙二醇干扰素α-2a，且不良反应发生率小。
목적：비교취을이순간우소α-2a여은체잡위치료만성을형간염환자적료효여안전성。방법장60례만성을형간염환자수궤분위간우소조30례화은체잡위조30례；2조균상규호간치료。간우소조급여취을이순간우소α-2a，은체잡위조령여은체잡위，관찰치료30주후2조환자적림상료효。결과치료후，2조병안산안기전태매（ALT）、천동안산안기전태매（AST）급총담홍소（TBIL）여치료전비교，간공능균유소개선（P<0.05）；은체잡위조적ALT복상솔（53.3%）、TBIL 복상솔（33.3%）화 HBV-DNA 전음솔（36.7%）명현고우간우소조적 ALT 복상솔（46.7%）、TBIL복상솔（30.0%）화HBV-DNA전음솔（20.0%），차이유통계학의의（ P<0.05）；간우소조（43.3%）적불량반응발생솔고우은체잡위조（10.0%），차이유통계학의의（ P<0.05）。결론은체잡위용우만성을형간염적항병독료효명현우우취을이순간우소α-2a，차불량반응발생솔소。
Objective To investigate clinical efficacy and safety of polyethylene glycol interferon alpha 2 a and ente-cavir(ETV)in the treatment of Chronic hepatitis B(CHB). Methods 60patients with CHB were divided into interferon group and ETV group;interferon group given polyethylene glycol interferon alpha 2 a,ETV group given ETV,Treatment course of two groups lasted for 30 weeks. Results After treatment,ALT、AST and TBIL of two groups were significantly lower than before,and there was statistically significant difference(P<0. 05);the recover rate of ALT、AST and the negative conversion rate of HBV-DNA in ETV group(53. 3%、33. 3%、36. 7%)were higher than interferon group(46. 7%、30. 0%、20. 0%), there was statistically significant difference(P<0. 05);the incidence rate of adverse reaction of interferon group(43. 3%) were higher than ETV group(10. 0%). Conclusion The antiviral effect of entecavir is better than polyethylene glycol inter-feron alpha 2 a in treatment of chronic hepatitis B,and has less adverse effects.